Provectus receives FDA guidance for late-stage trial of melanoma drug
KNOXVILLE, Tenn. — The Food and Drug Administration has provided guidance to Provectus Pharmaceuticals as the drug maker prepares to apply with the agency for approval to start a late-stage clinical trial of a drug for skin cancer, Provectus said Wednesday.
Provectus is planning to start a phase-3 trial of the investigational drug PV-10 for melanoma that has spread to other parts of the body, and said the FDA told the company that a meeting with the agency in addition to the one they had in October would not be required.
"Following our third meeting with the agency in October, we believed that significant progress had been achieved in defining the threshold the FDA will require for approval in melanoma, which is a rapidly evolving therapeutic area," Provectus CEO Craig Dees said.
Gilead completes acquisition of Pharmasset
FOSTER CITY, Calif. — Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.
The $137-per-share merger, originally announced in November 2011, makes Pharmasset a wholly owned subsidiary of Gilead. Pharmasset, based in Princeton, N.J., focuses on developing orally administered drugs for viral infections, particularly hepatitis C.
Harris Teeter helps customers save via pharmacy promotion
CHARLOTTE, N.C. — Harris Teeter has launched its Rx Punch Card promotion, which can help loyalty program customers save on groceries when they fill or transfer a prescription to one of the chain’s pharmacy locations.
As part of Rx Punch Card promotion, VIC loyalty program customers that transfer or fill a prescription will receive a $20 electronic coupon, which automatically will be applied to their card, for use on their next Harris Teeter grocery purchase of $20 or more. VIC households can earn up to 10, $20 coupons during the promotion for a total of $200 in savings, the company said.
The promotion runs through April 3.
Harris Teeter operates 136 pharmacy locations in six states, including Washington, D.C.